FDA approves Bristol-Myers Squibb's Opdivo Qvantig for subcutaneous use in adult solid tumors

From Nasdaq: 2024-12-27 22:33:24

The FDA approved Bristol Myers Squibb’s Opdivo Qvantig for subcutaneous use, a combination product of nivolumab and hyaluronidase-nvhy for adult solid tumors. Results from the Phase 3 CheckMate-67T trial showed non-inferior PK exposures, similar efficacy, and a comparable safety profile to IV Opdivo. Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor, offering faster delivery in three to five minutes compared to 30-minute IV Opdivo. This approval provides a new immunotherapy treatment option for patients. Visit rttnews.com for more health news.



Read more at Nasdaq: Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors